Protara Therapeutics Inc Sustainability Reports
Protara Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing transformative therapies for cancer and rare diseases. Its lead program includes TARA-002, an investigational cell therapy for non-muscle invasive bladder cancer and lymphatic malformations.
Sector: Manufacturing
Country: United States
Exchange: Nasdaq
LEI: 549300VWUGH3220TG273
FIGI: BBG001ZLYSK1
2 reports from 2022 to 2024
